Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery: Case report

Journal of Neurosurgery

Volumn 116, Issue 5, 2012, Pages 972-977

  Williams, Brian J ^a   Park, Deric M ^a   Sheehan, Jason P ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Arteriovenous malformation; Bevacizumab; Edema; Stereotactic radiosurgery

Indexed keywords

ALPHA TOCOPHEROL; BEVACIZUMAB; CORTICOSTEROID; PENTOXIFYLLINE;

ADULT; ARTICLE; BRAIN ARTERIOVENOUS MALFORMATION; BRAIN EDEMA; BRAIN PERILESIONAL EDEMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG TREATMENT FAILURE; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HEADACHE; HEMIPARESIS; HOSPITAL READMISSION; HUMAN; LIMB WEAKNESS; MOBILIZATION; NAUSEA; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE EDEMA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; WALKING DIFFICULTY;

ANGIOGENESIS INHIBITORS; ANGIOGRAPHY, DIGITAL SUBTRACTION; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN EDEMA; FEMALE; HEADACHE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MAGNETIC RESONANCE IMAGING; PARESIS; POSTOPERATIVE COMPLICATIONS; RADIOSURGERY; STEROIDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860713029     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.1.JNS111627     Document Type: Article

References (26)

1. Brinkerhoff BT, Poetker DM, Choong NW: Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 364:688-689, 2011
2. Bruce JN, Criscuolo GR, Merrill MJ, Moquin RR, Blacklock JB, Oldfield EH: Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg 67:880-884, 1987 (Pubitemid 18005534)
3. Chen S IV, Karnezis T, Davidson TM: Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis. Laryngoscope 121:644-646, 2011
4. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, et al: Impact of bevacizumab chemotherapy on craniotomy wound healing. Clinical article. J Neurosurg 114:1609-1616, 2011
5. Cohen MH, Shen YL, Keegan P, Pazdur R: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131-1138, 2009
6. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE II, Bailey L, et al: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer [epub ahead of print], 2011
7. Fodstad P, Dheyauldeen S, Rinde M, Bachmann-Harildstad G: Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 90:611-612, 2011
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
9. Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67:323-326, 2007 (Pubitemid 46108339)
10. Gronier S, Bourg V, Frenay M, Cohen M, Mondot L, Thomas P, et al: [Bevacizumab for the treatment of cerebral radionecrosis.] Rev Neurol (Paris) 167:331-336, 2011 (Fr)
11. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al: Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156-163, 2009
12. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, et al: Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 98:1400-1408, 1996 (Pubitemid 26322065)
13. Karnezis TT, Davidson TM: Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121:636-638, 2011
14. Kotsarini C, Griffiths PD, Wilkinson ID, Hoggard N: A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors. Neurosurgery 67:1799-1815, 2010
15. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
16. Liu AK, Macy ME, Foreman NK: Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 75:1148-1154, 2009
17. Matuschek C, Bölke E, Nawatny J, Hoffmann TK, Peiper M, Orth K, et al: Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol 187:135-139, 2011
18. Nonoguchi N, Miyatake S, Fukumoto M, Furuse M, Hiramatsu R, Kawabata S, et al: The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol 105:423-431, 2011
19. Papavassiliou E, Gogate N, Proescholdt M, Heiss JD, Walbridge S, Edwards NA, et al: Vascular endothelial growth factor (vascular permeability factor) expression in injured rat brain. J Neurosci Res 49:451-460, 1997 (Pubitemid 27353791)
20. Proescholdt MA, Heiss JD, Walbridge S, Mühlhauser J, Capogrossi MC, Oldfield EH, et al: Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol 58:613-627, 1999 (Pubitemid 29264941)
21. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, et al: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101: 1986-1994, 2009
22. Simonds J, Miller F, Mandel J, Davidson TM: The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119:988-992, 2009
23. Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, et al: Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94:63-68, 2009
24. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S: Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9:403-407, 2011
25. Yen CP, Jain S, Haq IU, Jagannathan J, Schlesinger D, Sheehan J, et al: Repeat Gamma Knife surgery for incompletely obliterated cerebral arteriovenous malformations. Neurosurgery 67:55-64, 2010
26. Yen CP, Khaled MA, Schwyzer L, Vorsic M, Dumont AS, Steiner L: Early draining vein occlusion after gamma knife surgery for arteriovenous malformations. Neurosurgery 67: 1293-1302, 2010